Search
Research
A Phase I/II, Multicentre, Observer-blinded, Randomized, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a combined Tetanus, Diphtheria, Acellular Pertussis and Poliomyelitis Vaccine (SIIPL Tdap-IPV) in CompariJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously primed with meningococcal ACWY vaccine (BOOST)Investigator: Peter Richmond Project description GSK is conducting a research study to evaluate its investigational, pentavalentmeningococcal vaccine
Research
BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) TrialJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years oPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Research
Sore Throat Melbourne and Perth Study: The Australian Strep A Vaccine Initiative (ASAVI) Urban Pharyngitis Surveillance Study (STAMPS)Jonathan Peter Carapetis AM Richmond AM MBBS FRACP FAFPHM PhD FAHMS MBBS MRCP(UK) FRACP Executive Director; Co-Head, Strep A Translation; Co-Founder
News & Events
Meningococcal vaccine provides extra protection for bubsIn 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.
News & Events
Perth mums play instrumental part in world-first vaccineNew mothers in Perth are teaming up with researchers at The Kids Research Institute Australia in a global bid to develop the first vaccine to prevent Respiratory Syncytial Virus (RSV) disease.
People
Professor Christopher BlythCentre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Honorary and NHMRC Career Development Fellow, Paediatric Infectious Diseases Physician and Clinical Microbiologist
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Research
Novel coenzyme Q6 genetic variant increases susceptibility to pneumococcal diseaseAcute lower respiratory tract infection (ALRI) remains a major worldwide cause of childhood mortality, compelling innovation in prevention and treatment. Children in Papua New Guinea (PNG) experience profound morbidity from ALRI caused by Streptococcus pneumoniae. As a result of evolutionary divergence, the human PNG population exhibits profound genetic variation and diversity. To address unmet health needs of children in PNG, we tested whether genetic variants increased ALRI morbidity.